Skip to main content
SpringerLink
Log in

Antifungal Agents

  • Chapter
  • First Online:
Diagnosis and Treatment of Fungal Infections

Part of the book series: Infectious Disease ((ID))

Abstract

Antifungal drugs used to treat serious fungal disease fall primarily into three drug classes. These classes include the azoles, echinocandins, and polyenes. Both azoles and polyenes target the cell membrane while echinocandins specifically target cell-wall synthesis. Amphotericin B is the primary drug in the polyene arsenal and is considered fungicidal, or capable of killing fungi. Remaining drugs are primarily fungistatic, meaning that they function by inhibiting growth and viability to assist the patient’s natural immunity in clearing infection. This chapter details drugs’ mechanism of action, spectrum of activity, pharmacokinetics, and previously reported adverse events.

In addition to drug characteristics and use, detection of resistance is discussed. Significant changes have been made in the interpretation of susceptibility testing results. Previously, break points were provided for all Candida spp., in general, but this has progressed to species-specific break points that are dependent on both the fungal species being tested and the drug under evaluation. In addition to making the break points species specific, the Clinical and Laboratory Standards Institute (CLSI) committee realized that the early break points were likely set too high. Current break points are approximately twofold lower than those previously published. Information regarding detecting resistance and incidence of resistance is discussed in regard to several clinically significant species.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect. 2004;10(Suppl 1):1–10.

    Article  CAS  PubMed  Google Scholar 

  2. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn Microbiol Infect Dis. 2004;48:101–5.

    Article  CAS  PubMed  Google Scholar 

  3. Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362:1142–51.

    Article  CAS  PubMed  Google Scholar 

  4. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11:272–9.

    Article  CAS  PubMed  Google Scholar 

  5. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol. 1998;44:343–500.

    Article  CAS  PubMed  Google Scholar 

  6. Kurtz MB, Rex JH. Glucan synthase inhibitors as antifungal agents. Adv Protein Chem. 2001;56:423–75.

    Article  CAS  PubMed  Google Scholar 

  7. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev. 1999;12:40–79.

    PubMed Central  CAS  PubMed  Google Scholar 

  8. Brüggemann RJM, Alffenaar J-WC, Blijlevens NMA, Billaud EM, Kosterink JGW, Verweij PE, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48:1441–58.

    Article  PubMed  Google Scholar 

  9. Gubbins PO, McConnell SA, Penzak SR. Antifungal agents. In Piscitelli SC, Rodvold KA, editors. Drug interactions in infectious diseases. Totowa: Humana Press; 2001. p. 185–217.

    Chapter  Google Scholar 

  10. Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362:1142–51.

    Article  CAS  PubMed  Google Scholar 

  11. Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev. 1993;6:1–21.

    PubMed Central  CAS  PubMed  Google Scholar 

  12. Kurtz MB, Heath IB, Marrinan J, Dreikorn S, Onishi J, Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother. 1994;38:1480–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. White TC. Mechanisms of resistance to antifungal agents. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, editors. Manual of Clinical Microbiology. 8th ed. Washington, DC: ASM Press; 2003. p. 1869–79.

    Google Scholar 

  14. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet. 2002;359:1135–44.

    Article  CAS  PubMed  Google Scholar 

  15. NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts; proposed standard. NCCLS document M27-P. Wayne: National Committee for Clinical Laboratory Standards; 1992.

    Google Scholar 

  16. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. CLSI document M27-A3. Wayne: Clinical and Laboratory Standards Institute; 2008.

    Google Scholar 

  17. CLSI. Reference method for broth dilution antifungal susceptibility testing of conidial-forming filamentous fungi. Approved standard. CLSI M38-A2. Wayne: Clinical and Laboratory Standards Institute; 2008.

    Google Scholar 

  18. NCCLS. Reference method for antifungal disk diffusion susceptibility testing of yeasts; Approved guideline. NCCLS document M44-A. Wayne: National Committee for Clinical Laboratory Standards; 2004.

    Google Scholar 

  19. CLSI. Method for antifungal disk diffusion susceptibility testing of nondermatophyte filamentous fungi; Approved guideline. CLSI M51-A. Wayne: Clinical and Laboratory Standards Institute; 2010.

    Google Scholar 

  20. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis. 2002;35:982–9.

    Article  CAS  PubMed  Google Scholar 

  21. Liu TT, Lee RE, Barker KS, et al. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob Agents Chemother. 2005;49:2226–36.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Marichal P, Gorrens J, Coene MC, Le Jeune L, Vanden Bossche H. Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Mycoses. 1995;38:111–7.

    Article  CAS  PubMed  Google Scholar 

  23. Schuetzer-Muehlbauer M, Willinger B, Krapf G, Enzinger S, Presterl E, Kuchler K. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol. 2003;48:225–35.

    Article  CAS  PubMed  Google Scholar 

  24. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56:1724–32.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW. FKS mutant Candida glabrata; risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014;59:819–25. (Advanced Access Published, July 9, 2014).

    Article  CAS  PubMed  Google Scholar 

  26. Tsai HF, Bard M, Izumikawa K, et al. Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension. Antimicrob Agents Chemother. 2004;48:2483–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Sanglard D, Ischer F, Marchetti O, Entenza J, Bille J. Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol Microbiol. 2003;48:959–76.

    Article  CAS  PubMed  Google Scholar 

  28. Heitman J. Cell biology. A fungal Achilles’ heel. Science. 2005;309:2175–6.

    Article  CAS  PubMed  Google Scholar 

  29. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science. 2005;309:2185–9.

    Article  CAS  PubMed  Google Scholar 

  30. Pappagianis D, Collins MS, Hector R, Remington J. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother. 1979;16:123–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Merz WG. Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol. 1984;20:1194–5.

    PubMed Central  CAS  PubMed  Google Scholar 

  32. Atkinson AJ, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother. 1978;13:271–6.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002;46:828–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis. 2003;36:943–51.

    Article  CAS  PubMed  Google Scholar 

  35. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. Brit Med J. 2001;322:579–82.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Pfaller MA, Messer SA, Hollis RJ, et al. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis. 1999;33:217–22.

    Article  CAS  PubMed  Google Scholar 

  37. Lewis RE. Pharmacotherapy of Candida bloodstream infections: new treatment options, new era. Expert Opin Pharmacother. 2002;3:1039–57.

    Article  CAS  PubMed  Google Scholar 

  38. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36:630–7.

    Article  CAS  PubMed  Google Scholar 

  39. Epaulard O, Villier C, Ravaud P, Chosidow O, Blanche S, Mamzer-Bruneel M-F, et al. A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French nationwide study. Clin Infect Dis. 2013;57:e182–8.

    Article  CAS  PubMed  Google Scholar 

  40. Clancy CJ, Nguyen MH. Long-term voriconazole and skin cancer: is there cause for concern? Curr Infect Dis Rep. 2011;6:536–43.

    Article  Google Scholar 

  41. Wermers RA, Cooper K, Razonable RR, Deziel PJ, Whitford GM, Kremers WK, et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis. 2011;52:604–11.

    Article  CAS  PubMed  Google Scholar 

  42. Malani AN, Kerr L, Obear J, Singal B, Kauffman CA. Alopecia and nail changes associated with Voriconazole therapy. Clin Infect Dis. 2014;59:e61–5.

    Article  PubMed  Google Scholar 

  43. Baxter CG, Marshall A, Roberts M, Felton TW, Denning DW. Peripheral neuropathy in patients on long-term triazole antifungal therapy. J Antimicrob Chemother. 2011;66:2136–9.

    Article  CAS  PubMed  Google Scholar 

  44. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet. 2005;44:211–20.

    Article  CAS  PubMed  Google Scholar 

  45. Percival KM, Bergman SJ. Update on posaconazole pharmacokinetics: comparison of old and new formulations. Curr Fungal Infect Rep. 2014;8:139–45.

    Article  Google Scholar 

  46. Merck & Co Inc. Noxafil Package Insert. 2014.

    Google Scholar 

  47. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood. 2004;103:1557–9.

    Article  CAS  PubMed  Google Scholar 

  48. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemothe. 2013;69:1162–76.

    Article  Google Scholar 

  49. Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol. 2004;126:165–75.

    Article  CAS  PubMed  Google Scholar 

  50. Day JN, Chau TTH, Wolbers M, Mai PP, Dung NT, Mai NH, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368:1291–302.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Marr K, Schlamm H, Rottinghaus S, Jagannatha S, et al. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment. In press.

    Google Scholar 

Suggested Reading

  • Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2013;69:1162–76.

    Article  PubMed Central  PubMed  Google Scholar 

  • Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokientics, safety and efficacy. Drugs. 2004:64:1997–2020.

    Article  CAS  PubMed  Google Scholar 

  • Gonzales GM, Fothergill AW, Sutton DA, Rinaldi MG, Lobenberg D. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol. 2005;43:281–4.

    Article  Google Scholar 

  • Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis. 2002;35:982–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fungus Testing Laboratory, Department of Pathology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, 78229, San Antonio, TX, Italy

    Russell E. Lewis

  2. Department of Medical Sciences and Surgery, University of Bologna & Infectious Diseases Unit, S. Orsola-Malpighi Hospital, Buiding 6 Via Massarenti, 11 40138, Bologna, Italy

    Annette W. Fothergill

Authors
  1. Russell E. Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annette W. Fothergill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annette W. Fothergill .

Editor information

Editors and Affiliations

  1. University Of Texas Health Science Cente, San Antonio, Texas, USA

    Duane R. Hospenthal

  2. University of Texas, San Antonio Health Science Center, San Antonio, Texas, USA

    Michael G. Rinaldi

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Lewis, R., Fothergill, A. (2015). Antifungal Agents. In: Hospenthal, D., Rinaldi, M. (eds) Diagnosis and Treatment of Fungal Infections. Infectious Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-13090-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-13090-3_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-13089-7

  • Online ISBN: 978-3-319-13090-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation